WARRINGTON, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage ...

WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for ...

Diabetic cardiomyopathy (DCM) is a progressive complication associated with type 2 diabetes (T2D), causing deterioration of cardiac function in diabetic patients, independent of coronary artery ...

Researchers have reported the long-term benefits of a single dose of their gene therapy AAV1/SERCA2a in advanced heart failure patients. Researchers from the Cardiovascular Research Center at Icahn ...

ePoster presentation advances the preclinical evaluation of the importance of SERCA2a function to reduce arrythmias with istaroxime and a selective SERCA2a activator in the setting of ischemia and ...

Figure 1: Endogenous SUMO1 protein levels are decreased in both experimental animal and human heart failure. Figure 2: SUMO1 is conjugated to lysines 480 and 585 of SERCA2a and is required for SERCA2a ...

Windtree Therapeutics, Inc. announced progress in its research on istaroxime and a selective SERCA2a activator, demonstrating a reduction in arrhythmias in an animal study, which will be presented at ...

Berlin, German y - In the first clinical test of a gene therapy for heart failure, administration of a gene that upregulates an enzyme involved in myocardial contraction and relaxation appeared to ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (OTCID: WINT) has strengthened its intellectual property position with newly allowed and granted patents in Canada, Mexico, and Israel, reinforcing the ...

A key abnormality in heart failure is defective handling of calcium ions by cardiomyocytes. In the healthy heart, the action potential leads to an increase in the level of intracellular calcium (and ...